Global Information
회사소개 | 문의 | 위시리스트

파머징 마켓 - 제품 종류별(의약품, 의료), 지역별(Tier I, Tier II, Tier III) : 시장 분석, 점유율, 동향, 규모, 예측

Pharmerging Market, By Product Types (Pharmaceuticals and Healthcare), By Geography (Tier I, Tier II and Tier III ) - Analysis, Share, Trends, Size, & Forecast From 2014 - 2025

리서치사 AnalystView Market Insights
발행일 2018년 07월 상품 코드 737891
페이지 정보 영문 99 Pages
가격
US $ 3,250 ₩ 3,885,000 PDF by E-mail (Single User Licence) help
1명만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 4,650 ₩ 5,558,000 PDF by E-mail (5 User Licence) help
동일 사업장 내 5명까지 이용할 수 있는 라이선스입니다. 인쇄 횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,650 ₩ 6,754,000 PDF by E-mail (Enterprise User Licence) help
동일 기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 및 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다.
자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



파머징 마켓 - 제품 종류별(의약품, 의료), 지역별(Tier I, Tier II, Tier III) : 시장 분석, 점유율, 동향, 규모, 예측 Pharmerging Market, By Product Types (Pharmaceuticals and Healthcare), By Geography (Tier I, Tier II and Tier III ) - Analysis, Share, Trends, Size, & Forecast From 2014 - 2025
발행일 : 2018년 07월 페이지 정보 : 영문 99 Pages

파머징 마켓(Pharmerging Market)에 대해 분석하고, 시장 정의와 기본 구조, 주요 시장 성장 촉진요인 및 억제요인, 업계의 경쟁력과 매력, 시장 점유율 구조, 분야별/Tier별 시장 동향 전망(과거 4년간, 향후 8년간), 주요 기업 개요 등에 대해 조사했습니다.

제1장 파머징 마켓(신흥 제약 시장) : 개요

제2장 개요

제3장 주요 시장 동향

  • 시장 성장 촉진요인
    • 성장 촉진요인의 영향도
  • 시장 성장 억제요인
    • 성장 억제요인의 영향도
  • 시장 기회
  • 시장의 향후 동향

제4장 산업 분석

  • Porter's Five Forces 분석
  • 시장의 매력 분석
  • 규제 프레임워크 분석

제5장 파머징 마켓 환경

  • 시장 점유율 분석

제6장 파머징 마켓 : 제품 종류별 분석

  • 개요
  • 의약품
    • 개요
    • 시장 규모 분석과 예측, 연간 성장률(금액 기준, 통산 12년간)
    • 특허 의약품
    • 제네릭 의약품
    • 일반약(OTC 의약품)
  • 의료
    • 의료기기
    • 체외(IV) 진단
    • 기타

제7장 파머징 마켓 : 지역별 분석

  • 서론
  • Tier I 시장 : 중국
    • 개요
    • 시장 규모 분석과 예측, 연간 성장률(금액 기준, 통산 12년간)
  • Tier II 시장 : 인도, 러시아, 브라질, 남아프리카공화국
  • Tier III 시장 : 터키, 폴란드, 멕시코, 아르헨티나, 태국, 사우디아라비아

제8장 주요 벤더 분석

  • Pfizer, Inc.
    • 기업 개요
    • SWOT 분석
    • 최근의 주요 동향
  • AstraZeneca
  • Roche
  • GE Healthcare
  • Medtronic

제9장 애널리스트의 전방위적 견해

제10장 부록

LSH 18.11.16

List of Tables

  • Table 1 List of Acronyms
  • Table 2 Key Market Facts, 2014 - 2025
  • Table 3 Market Drivers: Impact Analysis
  • Table 4 Market Restraint: Impact Analysis
  • Table 5 Market Opportunity: Impact Analysis
  • Table 6 PEST Analysis
  • Table 7 Porter's Five Forces Analysis
  • Table 8 Company Market Share Analysis
  • Table 9 Global Pharmerging Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • Table 10 Pharmerging Market, by Product Types, 2014 - 2025 (USD Billion)
  • Table 11 Pharmerging Market, by Geography, 2014 - 2025 (USD Billion)
  • Table 12 Tier I Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 13 China Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 14 Tier II Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 15 India Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 16 Russia Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 17 Brazil Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 18 South Africa Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 19 Tier III Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 20 Turkey Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 21 Poland Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 22 Mexico Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 23 Argentina Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 24 Thiland Pharmerging Market, 2014 - 2025 (USD Billion)
  • Table 25 Soudi Arabia Pharmerging Market, 2014 - 2025 (USD Billion)

List of Figures

  • Figure 1 Research Methodology
  • Figure 2 Research Process Flow Chart
  • Figure 3 Comparative Analysis, by Geography, 2016-2025 (Value %)
  • Figure 4 Regulatory Framework Analysis
  • Figure 5 Pharmerging Market, by Product Types, 2014 - 2025 (USD Billion)
  • Figure 6 Pharmerging Market, by Geography, 2014 - 2025 (USD Billion)

Report Hightlights

The Pharmerging market is estimated to represent a global market of USD 543.9 billion by 2017 with growth rate of 15.7%.

Market Dynamics

The pharmerging industry covers the study for developing countries where the use of pharmaceuticals is rapidly growing and is projected to experience strong growth in the future period. Countries such as China, India, Brazil, Russia, and South Africa among others are considered under the research scope. Drug spending in these economies is increasing at a constant rate, making them attractive targets for drug manufacturers to invest in. For instance, as per the International Federation of Pharmaceutical Manufacturers & Associations, pharmerging economies account for around 50% of absolute growth in drug spending every year.

There is a constant rise of people affected by chronic disorders due to the lifestyle changes. The number of cardiovascular, cancer, respiratory and diabetes patients are increasing monumentally. For example, cardiovascular conditions such as strokes, coronary heart disease, rheumatic heart disease, and cardiomyopathy are expected to be the major causes of mortality and morbidity in developing countries across the world. As per the World Health Organization statistics, more than 80% of cardiovascular deaths occur in low to middle-income countries. Additionally, an aging population, higher standards of living and advancement in technologies in the medical sector have led to a sharp increase in life expectancy. As a consequence, longer-lived individuals will create upward pressure on demand for pharmaceuticals & healthcare services. All such facts would in turn open up a new market for healthcare treatment that have traditionally been targeted at developed region patients.

Product Types Takeaway

In terms of product types, the industry is divided into Pharmaceuticals and Healthcare. Pharmaceuticals segment is further categorized as Patented, Generic and Over-the-Counter Therapeutics. In 2017, generic pharmaceuticals recorded USD 198.7 billion and the segment is projected to grow with strong CAGR during the future period. Healthcare segment is bifurcated as Medical Devices, In-Vitro Diagnostics, and others.

Regional Takeaway

Geographically, the industry is broadly categorized into Tier I, Tier II and Tier III economies. Chinese pharmerging market covers under the Tier I category which is considered one amongst the highest revenue generating country. In 2017, this category has captured over 52% of the worldwide market. According to China's Ministry of Finance (MOF), healthcare expenditure in the country has increased by 10% in 2016. Due to this fact, out-of-pocket spending for healthcare needs in China has decreased, as the penetration of insurance has increased. As of 2015, almost 95.0% of the population is enrolled in at least one public health insurance scheme.

Global Pharmerging Market, by Region, 2017 vs 2025

Tier II category include a detailed study for BRICS countries (except China) such as India, Russia, Brazil and South Africa. India and Brazil collectively accounted for over 60% revenue share of the countries considered under Tier II economy. As per the Pharmaceutical Export Promotion Council of India (PHARMEXCIL), the national pharmaceutical exports are projected to reach USD 20 million by 2020. The Indian pharmaceutical sector is highly fragmented with the presence of more than 15,000 manufactures. Tier III includes extensive qualitative and quantitative study for Turkey, Poland, Mexico, Argentina, Thailand, and Saudi Arabia. These countries represent a wide range of incomes, and GDP Mexico recorded USD 22.9 billion in 2017 and is projected to grow by over 8% CAGR during the study period.

Key Vendor Takeaway

Companies namely Pfizer, Inc., AstraZeneca, Roche, GE Healthcare, and Medtronic are actively operating in this industry. Attributes such as company overview, financials, product benchmarking and key initiatives were discussed separately. Key players are engaged in strategic collaborations to capture untapped market opportunities. For instance, in July 2017, AstraZeneca collaborated with Merck, Inc. to potential cancer therapeutic, MEK and PARP inhibitors in combination with PD-L1 medicines.

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year - 2014 & 2016

Base Year - 2017

Estimated Year - 2018

Projected Year - 2025

TARGET AUDIENCE

Traders, Distributors, and Suppliers

Manufacturers

Hospitals

Government and Regional Agencies and Research Organizations

Consultants

Distributors

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

MARKET, BY PRODUCT TYPES

Pharmaceuticals

Patented

Generic

Over-the-Counter

Healthcare

Medical Devices

In-Vitro Diagnostics

Others

MARKET, BY REGION

Tier I

China

Tier II

India

Russia

Brazil

South Africa

Tier III

Turkey

Poland

Mexico

Argentina

Thailand

Saudi Arabia

TABLE OF CONTENTS

1. PHARMERGING MARKET OVERVIEW

  • 1.1. Study Scope
  • 1.2. Assumption and Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Key Market Facts
  • 2.2. Geographical Scenario
  • 2.3. Companies in the Market

3. PHARMERGING KEY MARKET TRENDS

  • 3.1. Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Future Trends

4. PHARMERGING INDUSTRY STUDY

  • 4.1. Porter's Analysis
  • 4.2. Market Attractiveness Analysis
  • 4.3. Regulatory Framework Analysis

5. PHARMERGING MARKET LANDSCAPE

  • 5.1. Market Share Analysis

6. PHARMERGING MARKET - BY PRODUCT TYPES

  • 6.1. Overview
  • 6.2. Pharmaceuticals
    • 6.2.1. Overview
    • 6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 6.2.3. Patented
    • 6.2.3.1. Overview
    • 6.2.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 6.2.4. Generic
    • 6.2.4.1. Overview
    • 6.2.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 6.2.5. Over-the-Counter
    • 6.2.5.1. Overview
    • 6.2.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 6.3. Healthcare
    • 6.3.1. Overview
    • 6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 6.3.3. Medical Devices
    • 6.3.3.1. Overview
    • 6.3.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 6.3.4. In-Vitro Diagnostics
    • 6.3.4.1. Overview
    • 6.3.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 6.3.5. Others
    • 6.3.5.1. Overview
    • 6.3.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)

7. PHARMERGING MARKET- BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. Tier I
    • 7.2.1. Overview
    • 7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.2.3. China
    • 7.2.3.1. Overview
    • 7.2.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 7.3. Tier II
    • 7.3.1. Overview
    • 7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.3.3. India
    • 7.3.3.1. Overview
    • 7.3.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.3.4. Russia
    • 7.3.4.1. Overview
    • 7.3.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.3.5. Brazil
    • 7.3.5.1. Overview
    • 7.3.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.3.6. South Africa
    • 7.3.6.1. Overview
    • 7.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 7.4. Tier III
    • 7.4.1. Overview
    • 7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.4.3. Turkey
    • 7.4.3.1. Overview
    • 7.4.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.4.4. Poland
    • 7.4.4.1. Overview
    • 7.4.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.4.5. Mexico
    • 7.4.5.1. Overview
    • 7.4.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.4.6. Argentina
    • 7.4.6.1. Overview
    • 7.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.4.7. Thailand
    • 7.4.7.1. Overview
    • 7.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 7.4.8. Saudi Arabia
    • 7.4.8.1. Overview
    • 7.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)

8. KEY VENDOR ANALYSIS

  • 8.1. Pfizer, Inc.
    • 8.1.1. Company Overview
    • 8.1.2. SWOT Analysis
    • 8.1.3. Key Developments
  • 8.2. AstraZeneca
    • 8.2.1. Company Overview
    • 8.2.2. SWOT Analysis
    • 8.2.3. Key Developments
  • 8.3. Roche
    • 8.3.1. Company Overview
    • 8.3.2. SWOT Analysis
    • 8.3.3. Key Developments
  • 8.4. GE Healthcare
    • 8.4.1. Company Overview
    • 8.4.2. SWOT Analysis
    • 8.4.3. Key Developments
  • 8.5. Medtronic
    • 8.5.1. Company Overview
    • 8.5.2. SWOT Analysis
    • 8.5.3. Key Developments

Client can request additional company profiling as per specific requirements

9. 360 DEGREE ANALYSTVIEW

10. APPENDIX

  • 10.1. Research Methodology
  • 10.2. Abbreviations
  • 10.3. Disclaimer
  • 10.4. Contact Us
Back to Top
전화 문의
F A Q